Abstract:Background: Follow-up monitoring of islet autoantibody positive (IA+) persons is critical to early T1D identification, including prevention of diabetic ketoacidosis. We identified factors predicting completion of an initial follow-up monitoring visit after confirming high-risk IA+ (i.e., single IA+ by two methods or multiple IA+). Methods: The Autoimmunity Screening for Kids (ASK) program screens youth aged 1-17 for IA and offers a free monitoring program if the child is identified as IA+. Multiple logistic regression was used to identify factors associated with completing the initial monitoring visit among youth identified as high-risk for progressing to T1D (i.e., single IA+ by two methods or multiple IA+). Results: Seventy-nine percent (N=194/246) of youth completed an initial monitoring visit. Controlling for child age, sex, IA status, and race/ethnicity, youth with a first-degree relative with T1D (i.e., parent or sibling) were significantly less likely to participate in the monitoring visit (OR 0.39, p=0.04). Conclusion: Youth at high-risk for progression to T1D with FDRs were less likely to participate in the ASK follow-up monitoring program compared to individuals without FDRs. These findings are consistent with the TEDDY study which found FDRs were less likely to complete OGTTs and food records. Potential explanations include FDRs are more confident monitoring for signs/symptoms and therefore feel the visits are less necessary. Alternatively, the burden of caring for another individual with T1D already may make follow-up for the individual identified as high-risk less feasible. Further research is needed to better understand reasons FDRs are less engaged in follow-up after being identified as high-risk for T1D. Interventions tailored to address concerns of FDRs may help increase engagement in programs monitoring high-risk IA+ children for progression to clinical T1D. Disclosure H.K. O'Donnell: None. F. Dong: None. S.B. Johnson: None. C. Geno Rasmussen: None. B.I. Frohnert: None. A. Steck: None. K.A. Bautista: None. F. Sepulveda: None. M. Rewers: Advisory Panel; Sanofi. Other Relationship; Sanofi. Consultant; Janssen Pharmaceuticals, Inc. Research Support; Juvenile Diabetes Research Foundation (JDRF). Consultant; Provention Bio, Inc. Research Support; Hemsley Charitable Trust, National Institute of Diabetes and Digestive and Kidney Diseases. K.M. Simmons: Advisory Panel; Provention Bio, Inc. Consultant; Provention Bio, Inc. Research Support; Provention Bio, Inc., Novartis AG. Consultant; Medtronic. Funding National Institute of Diabetes and Digestive Kidney Disease (P30DK11607); The Helmsley Charitable Trust; Juvenile Diabetes Research Foundation

Follow-up and monitoring programme in children identified in early-stage type 1 diabetes during screening in the general population of Italy

General population screening for type 1 diabetes using islet autoantibodies at the preschool vaccination visit: a proof-of-concept study (the T1Early study)

Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes

Glucometrics and device satisfaction in children and adolescents with type 1 diabetes using different treatment modalities: A multicenter real-world observational study

Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes

Universal screening for early detection of chronic autoimmune, metabolic and cardiovascular diseases in the general population using capillary blood (UNISCREEN): low-risk interventional, single-centre, pilot study protocol

A strategy to find gene combinations that identify children who progress rapidly to type 1 diabetes after islet autoantibody seroconversion

Future acceptance of automated insulin delivery systems in youths with type 1 diabetes: validation of the Italian artificial pancreas-acceptance measure

1168-P: First-Degree Relatives with High-Risk Islet Autoantibodies Less Likely to Engage in Follow-up

Detection of Islet Autoantibodies in Whole Blood by Antibody Detection by Agglutination-PCR (ADAP) Technology Is Sensitive and Suitable for General Population Screening Programs

The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults

Childhood screening for type 1 diabetes comparing automated multiplex Antibody Detection by Agglutination-PCR (ADAP) with single plex islet autoantibody radiobinding assays

Accuracy of Serological Screening for the Diagnosis of Celiac Disease in Type 1 Diabetes Children

Home capillary sampling and screening for type 1 diabetes, celiac disease, and autoimmune thyroid disease in a Swedish general pediatric population: the TRIAD study

Presentation and characteristics of children with screen-detected type 1 diabetes: learnings from the ELSA general population pediatric screening study

Prevalence and detection rate of celiac disease in Italy: Results of a SIGENP multicenter screening in school-age children

Use of teplizumab in children and adolescents at risk of type 1 diabetes: perspectives of parents and caregivers from an Italian Pediatric Diabetes Center

Management of Type 1 Diabetes in a school setting: effectiveness of an online training program for school staff

Early Dysglycemia Is Detectable Using Continuous Glucose Monitoring in Very Young Children at Risk of Type 1 Diabetes

The real-life management of glucose homeostasis abnormalities in pediatric onco-hematological diseases: data from a national survey

Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1-year real-world assessment